The role of human papillomavirus in head and neck tumors
DOI:
https://doi.org/10.34631/sporl.624Keywords:
Human Papilloma Virus, tumors of the head and neck, DNA, alcohol, tobaccoAbstract
The human papillomavirus (HPV) infection is a risk factor for the development of tumors of the head and neck. We intend to assess the prevalence of HPV in these tumors in patients without alcohol and tobacco risk factors.
The presence of HPV DNA was tested by PCR (Polymerase Chain Reaction) in all patients with head and neck tumor identified between 2010 and 2013.
44 patients with a mean age of 61.4 years were identified, with a predominance of males. 6 of these patients were HPV-DNA positive, of which 50.0% had a stage IVA. 66.7% underwent surgery and the remaining systemic therapy. The HPV-DNA positive population’s overall survival at 12 and 60 months was 100% and 50%, respectively and the HPV-DNA negative population’s overall survival was 86.8% and 15.8%, respectively.
In our population, 13.6% of patients were positive for DNAHPV, which is comparable to published studies.
References
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108.
Marur S, D’Souza G, Westra WH, Forastiere AA (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11: 781–89.
Chaturvedi AK, Engels EA, Anderson WF, et al. (2008) Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26: 612-619
Mendenhall WM, Werming JW, Pflister DG (2008) Cancer of Head and Neck: Treatment of Head and Neck Cancers. In: Cancer: Principles and Practice of Oncology, 8th ed. (DeVita, VT, Lawrence, ST & Rosenberg, SA, eds.), pp809–77. Philadelphia: Lippincott, Williams & Wilkins.
D’Souza G, Kreimer AR, Viscidi R, et al. (2007) Case–control study of human
papillomavirus and oropharyngeal cancer. N Engl J Med 356: 1944–56.
Al-Awadhi R, Chehadeh W, Kapila K (2011) Prevalence of human papillomavirus among women with normal cervical cytology in Kuwait. J Med Virol. 83(3): 453–460.
World Health Organization (2007) IARC monographs on the evaluation of carcinogenic risks to humans: volume 90 - Human Papillomaviruses. Lyon: International Agency for Research on Cancer.
Shiboski CH, Schmidt BL, Jordan RC (2005) Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20–44 years. Cancer 103: 1843–49.
Muñoz N, Bosch FX, de Sanjosé S, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518–27.
Bouvard V, Baan R, Straif K, et al (2009) A review of human carcinogens--Part B: biological agents. Lancet Oncol 10:321–322.
Glombitza F, Guntinas-Lichius O, Petersen I (2010) HPV status in head and neck tumors. Pathology –ResearchandPractice 206:229–234.
Deng Z, Hasegawa M, Yamashita Y, et al (2012) Prognostic value of human papillomavirus and squamous cell carcinoma antigen in head and neck squamous cell carcinoma. Cancer Sci 103:2127–2134
Mehanna H, Jones TM, Gregoire V, et al (2012) Oropharyngeal carcinoma related to human papillomavirus. Bmj. 340:c1439
Kumar B et al (2007) Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. Int J Radiat Oncol Phys 69:109-111
Weinberger PM et al (2006) Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 245736-747
Efeyan A, Serrano (2007) M. p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 6:1006–1010.
Lee D, Kwon JH, Kim EH, et al (2010) HMGB2 stabilizes p53 by interfering with E6/E6AP-mediated p53 degradation in human papillomavirus-positive HeLa cells. Cancer Lett 292:125–132.
Westra WH, Taube JM, Poeta ML, et al (2008) Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res 14: 366–69.
Michaud WA, Nichols AC, Mroz EA, et al. (2009) Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res 15: 1645–54.
Kumar B, Cordell KG, Lee JS, et al. (2008) EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26: 3128–37.
Goon PK, Stanley MA, Ebmeyer J, et al. (2009). HPV & head and neck cancer: a descriptive update. Head neck oncology 1(1): 36.
Butz K, Geisen C, Ullmann A, et al (1996) Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7- oncogene expression and induction of apoptosis. Int J Cancer 68: 506–13.
Gillison ML, Koch WM, Capone RB, et al. (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92: 709–20.
Liu Y, McKalip A, Herman B (2000) Human papillomavirus type 16 E6 and HPV-16 E6/E7 sensitize human keratinocytes to apoptosis induced by chemotherapeutic agents: roles of p53 and caspase activation. J Cell Biochem 78: 334–49.
Wierzbicka M, Józefiak A, Jackowska J, et al. (2014) HPV vaccination in head and neck HPV-related pathologies. Otolaryngol Pol 68 (4):157-173.
